Please login to the form below

Not currently logged in
Email:
Password:

Jemperli

This page shows the latest Jemperli news and features for those working in and with pharma, biotech and healthcare.

GSK partners with iTeos Therapeutics on next-gen immuno-oncology drug

GSK partners with iTeos Therapeutics on next-gen immuno-oncology drug

GSK and iTeos are also planning to launch combination studies of the mAb with PD-1 inhibitor Jemperli (dostarlimab) in 2022.

Latest news

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....